Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The CD8 alpha-beta T-cell surface glycoprotein (CD8αβ) is a transmembrane heterodimeric co-receptor expressed primarily on cytotoxic CD8+ αβ T cells, consisting of CD8α and CD8β chains each with an extracellular IgV-like domain, flexible hinge, transmembrane domain, and cytoplasmic tail. It binds the α3 domain of MHC class I molecules to enhance T-cell receptor (TCR) affinity during antigen recognition, recruits Lck kinase via a zinc-stabilized interaction in the CD8α cytoplasmic tail to initiate TCR signaling through CD3 ITAM phosphorylation, localizes to lipid rafts for immunological synapse formation, and supports T-cell development including thymocyte selection and maturation into memory subsets. CD8αβ acts as a stronger co-stimulator than CD8αα homodimers due to better Lck recruitment, with structural features like conserved Ig folds, disulfide bonds, O-linked glycosylation in the hinge, and palmitoylation aiding function.
Blockade of CD8/MHC-I interaction, Modulation of T-cell activation, Promotion or abrogation of TCR signaling, Engineering into CAR T-cell hinges and transmembrane domains
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD8 alpha-beta T-cell surface glycoprotein (CD8αβ).